递归和探索合并,以建立一个主要的AI药物开发平台,目的是加速药物生产并降低成本。 Recursion and Exscientia merge to create a leading AI drug development platform, aiming to accelerate drug creation and cut costs.

Recuration and Excientia, AI药物发现中的两位领先者, 合并成一个垂直整合平台。 Recursion and Exscientia, two leaders in AI drug discovery, have merged to form a vertically-integrated platform. 该联合实体目前有10多个临床和临床前期方案、10个先进的发现方案和10多个伙伴方案。 The combined entity now has over 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs. 合并有可能达到200多亿美元的里程碑付款,其目的是加快药物开发,降低成本,并通过先进的AI技术进行创新。 With potential for over $20 billion in milestone payments, the merger aims to accelerate drug development, reduce costs, and innovate through advanced AI technologies.